Purpose: Long-acting injectable antipsychotics (LAI) can optimize adherence for high-risk serious mental illness (SMI). This customized adherenceenhancement approach delivered by social worker interventionists was combined with LAI (CAE-L) of paliperidone palmitate for homeless, poorly adherent individuals with SMI.
R ecovery of individuals with serious mental illness (SMI) may be complicated by problems such as homelessness, substance use, and poor adherence.
1,2 Long-acting injectable antipsychotic (LAI) medication may improve adherence 3 ; however, recovery comprises more than just medication taking. Whitley and Drake 4 noted 5 key SMI recovery domains that include clinical recovery (reducing symptoms), existential recovery (hope and empowerment), functional recovery (housing, employment), physical recovery (medical health), and social recovery (social connections, community).
In homeless and poorly adherent persons with SMI, a treatment approach combining customized adherence enhancement + LAI (CAE-L) may reduce homelessness, improve SMI symptoms, and increase functioning. 5 Customized adherence enhancement + LAI is a manualized intervention that is highly acceptable to homeless people with SMI. 5 However, despite promising preliminary results, previous versions of CAE-L had barriers to scale-up. While delivery by a PhD-level psychologist is effective, many public-sector clinical settings have a very limited number of such highly trained individuals. In addition, CAE-L used first-generation LAI (haloperidol deaconate), which, although affordable, was associated with akathisia in 40% of people. To increase potential generalizability, the CAE-L intervention was modified to be delivered by social workers and featured a second-generation LAI (paliperidone palmitate). [6] [7] [8] This prospective 6-month, noncontrolled trial of modified CAE-L assessed multiple domains of recovery outcomes in 30 homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.
MATERIALS AND METHODS

Overview
Customized adherence enhancement + LAI combined an adherence-enhancement psychosocial intervention and LAI delivered prospectively over 6 months. Once intolerance to antipsychotic drug was ruled out, individuals received monthly LAI delivered concurrently with 30-to 60-minute interactive individual sessions based on cognitive-behavioral principles delivered by a trained social worker. Research assessments were conducted at screening, baseline, and at 13-and 25-week follow-up. Primary outcome was change in adherence as measured with the Tablets Routine Questionnaire (TRQ) and LAI injection frequency. Additional outcomes included housing status, SMI symptoms, global psychopathology, general and social functioning, hospitalization counts, satisfaction with treatment, extrapyramidal symptoms, and reported adverse effects.
Participants
Individuals, recruited from the community, were all 18 years or older with schizophrenia or schizoaffective disorder as confirmed by the Mini International Psychiatric Inventory version 6.0. 9 Participants had been homeless within the past 12 months and had poor adherence with oral antipsychotics defined as missing at least 20% of medication in the last week or month on the TRQ. 10, 11 Individuals on LAI immediately prior to enrollment and those with clozapine use, significant medical conditions, and/or substance dependence were excluded. The study was approved by the local institutional review board. Individuals were compensated for research assessments. Individuals were encouraged to continue care in their standard setting, mainly community mental health clinics (CMHCs).
CAE-L Intervention
Long-Acting Injectable Antipsychotic
Paliperidone palmitate was dosed as per manufacturer's package insert (https://www.invegasustenna.com). After the initial loading dose, paliperidone palmitate was administered every 4 weeks in the deltoid muscle for a total of 6 months. Individuals not on any antipsychotic or on antipsychotics other than paliperidone or risperidone at screening were given oral paliperidone (3 mg daily) for 3 days as an oral tolerance test. The LAI dosing was based on clinical judgement of the treating research psychiatrist.
Customized Adherence Enhancement
Customized adherence enhancement, originally designed for nonadherent patients with bipolar disorder, 12 targets key areas relevant to nonadherent individuals with SMI broadly and includes 4 flexibly administered modules based on baseline evaluation of 4 key adherence barriers: (1) psychoeducation focused on the role of medication in SMI recovery, (2) developing medication and lifestyle routines, (3) communicating with providers, and (4) managing adherence in the context of substance abuse. The CAE interventionist was a social worker who also reached out and worked with CMHCs to enhance adherence and help facilitate LAI continuation as clinically indicated over the long term. One social worker interventionist was trained and supervised by 1 PhD-level clinical psychologist on CAE administration. Training included videotaping intervention sessions with the psychologist reviewing the recordings and providing input to the social worker in addition to regular research review meetings approximately weekly.
Concomitant Treatments
Antipsychotic drugs other than LAI were discontinued with the exception of low-dose bedtime oral antipsychotic (ie, quetiapine 50-100 mg) for insomnia in a small number of individuals unable to be weaned off these drugs. Stable doses of psychotropic drugs other than antipsychotics were continued through the course of the study. New psychotropic medications were strongly discouraged. Medications for extrapyramidal side effects were given at the discretion of the treating psychiatrist.
Study Assessments
Participants were assessed at screening, baseline (first administration of LAI or first CAE session), and at 13 and 25 weeks' follow-up. The primary study outcome was adherence behavior assessed via the TRQ and LAI injection frequency. Raters trained to preset acceptability standards who were not involved in the study intervention performed the assessments.
Primary Outcomes
The TRQ 10, 11 determines the proportion of prescribed medication missed and ranges from 0 (no medication missed/100% adherent) to 100 (no medication taken/0% adherent). For this trial, the TRQ captured an exact proportion (%) of days with a missed medication dose for each maintenance oral psychotropic drug and derived an average combined TRQ. Full LAI adherence was defined as receiving an injection within 7 days of scheduled time.
Secondary Outcomes
Secondary outcomes included self-reported housing status, adherence attitudes, hospitalization count, SMI symptoms, social functioning, treatment satisfaction, adverse effects, and biological/ safety measures. Suboptimal housing was defined as incarceration, outside, transitional housing, homeless shelter, or temporary/ overnight stays with individuals in their social network. Days in suboptimal housing were assessed in the 6 months prior to study enrollment and during the 6-month study. The 10-item Drug Attitude Inventory 13 and the Attitudes Toward Mood Stabilizers Questionnaire (AMSQ), adapted from the Lithium Attitudes Questionnaire, 14 measured medication attitudes. Use of emergency care and hospitalization resources in the 6 months before and after study enrollment were evaluated. Serious mental illness symptoms were measured with the Positive and Negative Syndrome Scale (PANSS), 15 Brief Psychiatric Rating Scale (BPRS), 16 and the Clinical Global Impressions (CGI). 17 Functional status was evaluated with the Social and Occupational Functioning Assessment Scale (SOFAS). 18 The Alcohol, Smoking, and Substance Involvement Screening Test measured drug use. 19 Safety evaluations included baseline and week 25 (or end of study) comprehensive metabolic panel, lipid profile, complete blood count with differential, and pregnancy testing for women. Electrocardiography was conducted at baseline and week 25 (or end of study). Vital signs and weight were collected at each study visit. Measures of involuntary movements were the Simpson Angus Scale (SAS), 20 Barnes Akathisia Rating Scale (BARS), 21 Abnormal Involuntary Movement Scale (AIMS), 17 and the Extrapyramidal Symptoms Scale-Abbreviated version (ESRS-A). 22 Reported adverse effects were evaluated at each study visit. To assess generalizability of CAE-L, we assessed regular clinical care retention and patient satisfaction after the study via telephone 3 months after the last in-person visit.
Data Analysis
Descriptive statistics were calculated for baseline characteristics. Change was measured by taking differences in scores across time points. Hypothesis tests for assessing whether the median difference scores are zero were conducted using Wilcoxon signed rank test. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 23.0 (Armonk, NY). Figure 1 shows the study flow. The average time between screening and baseline was 7.37 (SD, 5.67) days. Mean sample age was 43.6 (SD, 9.53)years; 86.7% were African American, and 72.4% were single/never married, with a mean of 11.55 years of education. Baseline rate of substance abuse within the past year was 40.0%, and the rate of incarceration within the 6 months prior to enrollment was 32.1%. In the 6 months prior to study enrollment, participants spent 40% of their time in suboptimal housing. 
RESULTS
Study Flow and Sample
Dropouts and Safety
Four individuals (13.3%) terminated enrollment in the study prematurely. Reasons for dropout included 2 (50%) having been lost to follow-up, 1 relocated (25%), and 1 withdrew consent (25%). There were 7 serious adverse events that occurred in 5 individuals: 1 psychiatric hospitalization, 5 medical hospitalizations (hernia, respiratory/chronic obstructive pulmonary disease exacerbation, frostbite, spider bite, and elevated liver function and QTc prolongation on electrocardiography in the context of acute alcoholic hepatitis), and 1 emergency room visit due to falls. Two serious adverse events were possibly related to study drug (falls, worsened alcoholic hepatitis).
Efficacy and Adverse Effects
As shown in Table 1 , CAE-L was associated with good LAI adherence (90.5%) and improved oral drug adherence (P = 0.02). There were improvements in AMSQ (P = 0.01), BPRS (P = 0.01), PANSS (P < 0.001), CGI (P < 0.001), SOFAS (P < 0.001), and psychiatric hospitalizations (P = 0.03). There was a trend for reduced days in suboptimal housing (P = 0.05). The most common adverse effect (57%) was injection site complaints. There were no serious or sustained injection site reactions. Thirteen individuals (33%) experienced at least mild akathisia at some point during the trial, but only 1 akathisia case persisted at 6 months. One individual was discontinued because of adverse effects, a reported dystonic reaction after the first LAI injection. There were no significant changes on AIMS, SAS, BARS, and ESRS-A. Mean weight gain was 5.85 kg (SD, 9.35 kg), and median gain was 4.99 kg (range, −10.43 to 31.30 kg), with 9 (30%) individuals gaining more than 7% of their body weight. There was no significant change in laboratory testing.
Of individuals who completed 25 weeks of CAE-L, 21 (80.8%) provided poststudy information. Nineteen (90.5%) were still in CMHC care. Overall, 17 (81.0%) were very satisfied and 4 (19.0%) were satisfied with CAE-L and felt it was worth their time and effort. Of individuals who stopped LAI post-study, nine (42.9%) said they missed injections because the study ended: 5 (62.5%) chose to end their injections because of adverse effects, 2 (28.6%) missed because of either lack of transportation or inconvenience in getting the injection, 1 (14.3%) was incarcerated, and 1 individual (14.3%) missed because of medication access problems.
DISCUSSION
Combining LAI with a psychosocial intervention that targets individual barriers to adherence may improve multiple outcomes in homeless individuals with SMI. Findings from this trial generally replicated findings from an earlier pilot study. 5 Refinements of the CAE-L approach that are intended to facilitate broad scale-up included use of social workers to deliver the intervention and the use of a second-generation antipsychotic drug as LAI. Paliperidone palmitate was generally well tolerated, with injection site complaints being the most common problem. Weight gain was relatively common, with approximately 30% of individuals gaining more than 7% of their body weight. Although many second-generation antipsychotic drugs are associated with weight gain, 23 some of the weight gain in this sample could have been related to lifestyle issues seen in those residing in shelters or transitional housing. The formulation of paliperidone palmitate used in this study was the monthly injection version. Recently, a formulation of paliperidone palmitate that seems safe and effective when given every 3 months has become available. 24 It is possible that this strategy could further protect against future adherence-related relapse and could be an approach that might help retain individuals on LAI for longer periods.
Future implementation considerations might include embedding CAE-L directly into settings where homeless individuals present for crisis services such as temporary or homeless shelters. Another target might be prior to release from correctional settings. Notably, approximately one-third of our sample had been incarcerated in the 6 months prior to study entry.
There are few established treatments for homeless people with SMI, 25 and it is perhaps not surprising that their prognosis is often poor. 26 A literature review by Zhornitsky and Stip 27 suggested that LAIs reduce risk of relapse when combined with psychosocial interventions in some patients. While CAE-L was designed as an intervention to get very high-risk patients stabilized and on the road to recovery, it is encouraging that observed improvements in this trial suggest progress in several of the key recovery domains articulated by Whitley and Drake. 4 Clinical recovery was demonstrated by SMI symptomatic improvement (PANSS, BPRS, CGI), whereas functional recovery was demonstrated by reduced use of hospital services and a trend for improvement in housing status. Other domains of improvement included dramatic reduction in missed medication from 57.7% missed medication at screening versus 22% at 6-month follow-up and improved attitudes toward treatment and medication. Adherence behavior and attitudinal change could be indicators of empowerment and health ownership, although these constructs were not measured explicitly. Lastly, social functioning was improved in the sample. A recent qualitative analysis of trajectories of recovery among formerly homeless adults with SMI 2 noted that significant-other relationships were a top contributor to recovery change.
This study had a number of limitations including small sample size, an observational/noncontrolled design, unblinded assignment and assessment, and the single-site setting. However, findings are similar to a nearly identical trial conducted by this study team, which used haloperidol decanoate as LAI. It seems reasonable to cautiously conclude that a personalized intervention to address adherence barriers combined with LAI can improve adherence and selected recovery outcomes in high-risk individuals with SMI. 28 A pooled analysis of the 2 CAE-L studies conducted by this team found that dropout rate trended lower in the modified version, which featured social worker interventionists and secondgeneration LAI (13.3%), versus the original version, which used a PhD psychologist interventionist and first-generation LAI (33.3%) (P = 0.08). 28 Demographic and clinical features did not predict dropout, and most dropouts occurred in the early portion of the original trial [mean of 58.8 (SD, 36.0) days and 56.0 (SD, 42.0] days in the modified CAE-L trial. Completers had significant improvement in adherence, psychiatric symptoms, global psychopathology, and functioning.
In conclusion, a manualized adherence-enhancement approach that targets adherence barriers, uses social workers as interventionists, and is appropriate for both first-and second-generation LAIs may help recovery in some high-risk individuals with SMI. Controlled and larger studies that include additional assessments such as LAI drug levels are needed to confirm preliminary findings.
